TELO shares preclinical Telomir-1 data in PANC-1 cell model

Rhea-AI Filing Summary

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical findings showing that its small molecule Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The compound produced a concentration-dependent decrease in cell viability and mitochondrial activity, aligning with prior results in triple‑negative breast and prostate cancer models.

The response in pancreatic cells was partially reversed by iron re‑addition, indicating iron‑dependent processes contribute to the effect, while incomplete rescue suggests additional metabolic or epigenetic mechanisms. Telomir-1 has been associated with tumor suppressor genes and iron‑dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B, and KDM6B. The company noted pancreatic cancer’s five‑year survival rate is about 12 percent. Telomir plans to expand preclinical research to additional models, including leukemia, and to initiate in vivo validation studies as part of ongoing IND preparation.

Insights

Biotech R&D Analyst

Preclinical in vitro signal; early-stage and nonclinical.

The update describes in vitro activity of Telomir-1 in PANC-1 pancreatic cancer cells, with concentration‑dependent reductions in viability and mitochondrial activity. The iron re‑addition partial reversal points to iron‑dependent biology while implying other pathways may be involved.

Mechanistically, references to MASPIN, RASSF1A, STAT1, KDM2B, and KDM6B tie the findings to epigenetic and metabolic regulators frequently dysregulated in aggressive tumors. These are laboratory observations and do not establish clinical efficacy.

The company plans to broaden preclinical work and start in vivo validation as part of IND preparation. Actual impact will depend on forthcoming in vivo data and regulatory steps disclosed in subsequent filings.

false 0001971532 0001971532 2025-10-14 2025-10-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 14, 2025

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida, 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s consistent impact on cancer cell survival pathways.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) (“Telomir” or the “Company”) announced new laboratory findings demonstrating that Telomir-1 reduced the survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. Telomir-1 produced a concentration-dependent decrease in cell viability and mitochondrial activity, suggesting influence on cellular pathways related to energy metabolism and oxidative balance. These observations are consistent with previously reported data in triple-negative breast and prostate cancer models.

Similar to TNBC, Telomir-1’s effects in pancreatic cancer cells were partially reversed by iron re-addition, indicating that iron-dependent processes contribute to the response. The incomplete rescue supports the interpretation that additional metabolic or epigenetic mechanisms are engaged in pancreatic models.

Telomir-1 has previously been shown to influence tumor suppressor genes and iron-dependent histone demethylases that are relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B (FBXL10), and KDM6B (JMJD3). These genes and enzymes are known to govern DNA-methylation balance, oxidative stress response, and cellular energy regulation and are frequently dysregulated in aggressive tumor types.

The Company noted that pancreatic cancer is among the most difficult malignancies to treat, with a five-year survival rate of approximately 12 percent. Current standards of care—FOLFIRINOX and gemcitabine plus nab-paclitaxel—are limited by systemic toxicity and the rapid development of resistance. Telomir-1 is being evaluated preclinically for its ability to modulate epigenetic and metabolic regulators that contribute to cancer-cell survival and adaptation.

Telomir plans to expand its preclinical research to additional cancer models, including leukemia, and to initiate in vivo validation studies as part of its ongoing Investigational New Drug (IND) preparation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: October 14, 2025	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer

FAQ

What did Telomir Pharmaceuticals (TELO) announce in this update?

The company reported that Telomir-1 reduced survival of human pancreatic cancer (PANC-1) cells in vitro, with concentration-dependent effects on viability and mitochondrial activity.

Which cancer models has Telomir-1 affected according to TELO?

Findings complement prior results in triple-negative breast cancer and prostate cancer models, and now include PANC-1 pancreatic cancer cells.

What mechanism clues were observed in TELO’s pancreatic cell data?

Effects were partially reversed by iron re‑addition, indicating iron‑dependent processes, with additional metabolic or epigenetic mechanisms likely engaged.

Which genes and enzymes are highlighted as relevant by Telomir (TELO)?

MASPIN (SERPINB5), RASSF1A, STAT1, and iron‑dependent histone demethylases KDM2B (FBXL10) and KDM6B (JMJD3).

What is the context for pancreatic cancer severity noted by TELO?

Pancreatic cancer has a five‑year survival rate of approximately 12 percent, and current standards of care face toxicity and resistance challenges.

What are the next steps for Telomir-1 mentioned by TELO?

The company plans to expand preclinical research to additional models, including leukemia, and initiate in vivo validation studies as part of IND preparation.